Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study. J of Skin. 2019;3:S34. doi:10.25251/skin.3.supp.34